Global investment giant Ardian has reinvested in Italian pharmaceutical commercialisation business Neopharmed.
The deal comes four years after Ardian picked up a stake in the business, which was then the therapeutics unit of Italian drugmaker Mediolanum Farmaceutici.
Neopharmed’s buy-and-build strategy since Ardian’s investments has seen it bolt-on six businesses, and reach revenues of €250m.
Read more: Alt Assets
